{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T04:05:51Z","timestamp":1791691551952,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Peritoneal dialysis (PD) is an essential lifesaving treatment for end-stage renal disease. However, PD therapy is limited by peritoneal inflammation, which leads to peritoneal membrane failure because of progressive peritoneal deterioration. Peritonitis is the most common complication in patients undergoing PD. Thus, elucidating the mechanism of chronic peritoneal inflammation after PD-associated peritonitis is an urgent issue for patients undergoing PD. This first case report suggests that an increased interleukin-1\u03b2 (IL-1\u03b2) expression in the peritoneal dialysate after healing of peritonitis can contribute to peritoneal deterioration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 64-year-old woman was diagnosed with diabetes mellitus 10\u00a0years ago and had been started on PD for end-stage renal disease. One day, the patient developed PD-associated acute peritonitis and was admitted to our hospital for treatment. Thus, treatment with antimicrobial agents was initiated for PD-associated peritonitis. Dialysate turbidity gradually disappeared after treatment with antimicrobial agents, and the number of cells in the PD fluid decreased. After 2\u00a0weeks of antimicrobial therapy, peritonitis was clinically cured, and the patient was discharged. Thereafter, the patient did not develop peritonitis; however, residual renal function tended to decline, and peritoneal function also decreased in a relatively short period. We evaluated pro-inflammatory cytokine levels before and after PD-associated peritonitis; interestingly, the levels of IL-1\u03b2 remained high in the PD fluid, even after remission of bacterial peritonitis. In addition, it correlated with decreased peritoneal function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case suggests that inflammasome-derived pro-inflammatory cytokines may contribute to chronic inflammation-induced peritoneal deterioration after PD-related peritonitis is cured.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03431-8","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T13:01:58Z","timestamp":1702990918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["IL-1\u03b2 may be an indicator of peritoneal deterioration after healing of peritoneal dialysis-associated peritonitis"],"prefix":"10.1186","volume":"24","author":[{"given":"Akira","family":"Hirano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kadoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"3","key":"3431_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1681\/ASN.2011060607","volume":"23","author":"AK Jain","year":"2012","unstructured":"Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012;23(3):533\u201344.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3431_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2215\/CJN.07920910","volume":"6","author":"K Chaudhary","year":"2011","unstructured":"Chaudhary K, Sangha H, Khanna R. Peritoneal dialysis first: rationale. Clin J Am Soc Nephrol. 2011;6(2):447\u201356.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"3431_CR3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1681\/ASN.V971285","volume":"9","author":"DN Churchill","year":"1998","unstructured":"Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol. 1998;9(7):1285\u201392.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"3431_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nrneph.2012.144","volume":"8","author":"A Pletinck","year":"2012","unstructured":"Pletinck A, Vanholder R, Veys N, Van Biesen W. Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions. Nat Rev Nephrol. 2012;8(9):542\u201350.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"3431_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/ndt\/gfz298","volume":"35","author":"H Kadoya","year":"2020","unstructured":"Kadoya H, Satoh M, Nishi Y, Kondo M, Wada Y, Sogawa Y, et al. Klotho is a novel therapeutic target in peritoneal fibrosis via Wnt signaling inhibition. Nephrol Dial Transplant. 2020;35(5):773\u201381.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"3431_CR6","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1681\/ASN.2006111292","volume":"18","author":"LS Aroeira","year":"2007","unstructured":"Aroeira LS, Aguilera A, Sanchez-Tomero JA, Bajo MA, del Peso G, Jimenez-Heffernan JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol. 2007;18(7):2004\u201313.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3431_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1159\/000448437","volume":"8","author":"H Herwald","year":"2016","unstructured":"Herwald H, Egesten A. On PAMPs and DAMPs. J Innate Immun. 2016;8(5):427\u20138.","journal-title":"J Innate Immun"},{"issue":"6","key":"3431_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.cell.2014.02.008","volume":"156","author":"A Lu","year":"2014","unstructured":"Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell. 2014;156(6):1193\u2013206.","journal-title":"Cell"},{"issue":"10","key":"3431_CR9","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2010020143","volume":"21","author":"A Vilaysane","year":"2010","unstructured":"Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21(10):1732\u201344.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"3431_CR10","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","volume":"122","author":"A Grebe","year":"2018","unstructured":"Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Circ Res. 2018;122(12):1722\u201340.","journal-title":"Circ Res"},{"key":"3431_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fimmu.2013.00050","volume":"4","author":"RW Grant","year":"2013","unstructured":"Grant RW, Dixit VD. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front Immunol. 2013;4:50.","journal-title":"Front Immunol"},{"issue":"6","key":"3431_CR12","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/ndt\/16.6.1262","volume":"16","author":"Y Ishii","year":"2001","unstructured":"Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant. 2001;16(6):1262\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"3431_CR13","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1096\/fj.15-271734","volume":"29","author":"H Kadoya","year":"2015","unstructured":"Kadoya H, Satoh M, Sasaki T, Taniguchi S, Takahashi M, Kashihara N. Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis in mice. FASEB J. 2015;29(9):3899\u2013910.","journal-title":"FASEB J"},{"issue":"7","key":"3431_CR14","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1681\/ASN.2016070729","volume":"28","author":"N Hautem","year":"2017","unstructured":"Hautem N, Morelle J, Sow A, Corbet C, Feron O, Goffin E, et al. The NLRP3 inflammasome has a critical role in peritoneal dialysis-related peritonitis. J Am Soc Nephrol. 2017;28(7):2038\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3431_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1681\/ASN.V132470","volume":"13","author":"JD Williams","year":"2002","unstructured":"Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13(2):470\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"3431_CR16","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1093\/ndt\/gfq771","volume":"26","author":"T Bellon","year":"2011","unstructured":"Bellon T, Martinez V, Lucendo B, del Peso G, Castro MJ, Aroeira LS, et al. Alternative activation of macrophages in human peritoneum: implications for peritoneal fibrosis. Nephrol Dial Transplant. 2011;26(9):2995\u20133005.","journal-title":"Nephrol Dial Transplant"},{"key":"3431_CR17","doi-asserted-by":"publisher","first-page":"715209","DOI":"10.3389\/fimmu.2021.715209","volume":"12","author":"TE Sutherland","year":"2021","unstructured":"Sutherland TE, Shaw TN, Lennon R, Herrick SE, Ruckerl D. Ongoing exposure to peritoneal dialysis fluid alters resident peritoneal macrophage phenotype and activation propensity. Front Immunol. 2021;12:715209.","journal-title":"Front Immunol"},{"key":"3431_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2017.12.023","volume":"94","author":"Q Li","year":"2018","unstructured":"Li Q, Zheng M, Liu Y, Sun W, Shi J, Ni J, et al. A pathogenetic role for M1 macrophages in peritoneal dialysis-associated fibrosis. Mol Immunol. 2018;94:131\u20139.","journal-title":"Mol Immunol"},{"issue":"5","key":"3431_CR19","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.kint.2016.10.030","volume":"91","author":"CT Liao","year":"2017","unstructured":"Liao CT, Andrews R, Wallace LE, Khan MW, Kift-Morgan A, Topley N, et al. Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes. Kidney Int. 2017;91(5):1088\u2013103.","journal-title":"Kidney Int"},{"issue":"9","key":"3431_CR20","doi-asserted-by":"publisher","first-page":"e23129","DOI":"10.1096\/fj.202201777RRR","volume":"37","author":"H Kadoya","year":"2023","unstructured":"Kadoya H, Hirano A, Umeno R, Kajimoto E, Iwakura T, Kondo M, et al. Activation of the inflammasome drives peritoneal deterioration in a mouse model of peritoneal fibrosis. FASEB J. 2023;37(9):e23129.","journal-title":"FASEB J"},{"key":"3431_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fimmu.2015.00068","volume":"6","author":"B McDonald","year":"2015","unstructured":"McDonald B, Kubes P. Interactions between CD44 and Hyaluronan in Leukocyte Trafficking. Front Immunol. 2015;6:68.","journal-title":"Front Immunol"},{"issue":"2","key":"3431_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/089686089901900210","volume":"19","author":"K Yamagata","year":"1999","unstructured":"Yamagata K, Tomida C, Koyama A. Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999;19(2):131\u20137.","journal-title":"Perit Dial Int"},{"issue":"19","key":"3431_CR23","doi-asserted-by":"publisher","first-page":"12762","DOI":"10.1074\/jbc.M806084200","volume":"284","author":"K Yamasaki","year":"2009","unstructured":"Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J, et al. NLRP3\/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem. 2009;284(19):12762\u201371.","journal-title":"J Biol Chem"},{"issue":"6","key":"3431_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1089\/sur.2012.195","volume":"14","author":"CC Tsai","year":"2013","unstructured":"Tsai CC, Lee JJ, Liu TP, Ko WC, Wu CJ, Pan CF, et al. Effects of age and diabetes mellitus on clinical outcomes in patients with peritoneal dialysis-related peritonitis. Surg Infect (Larchmt). 2013;14(6):540\u20136.","journal-title":"Surg Infect (Larchmt)"},{"issue":"4","key":"3431_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10157-013-0872-y","volume":"18","author":"M Nishina","year":"2014","unstructured":"Nishina M, Yanagi H, Kakuta T, Endoh M, Fukagawa M, Takagi A. A 10-year retrospective cohort study on the risk factors for peritoneal dialysis-related peritonitis: a single-center study at Tokai University Hospital. Clin Exp Nephrol. 2014;18(4):649\u201354.","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"3431_CR26","doi-asserted-by":"publisher","first-page":"e0225316","DOI":"10.1371\/journal.pone.0225316","volume":"14","author":"R Ueda","year":"2019","unstructured":"Ueda R, Nakao M, Maruyama Y, Nakashima A, Yamamoto I, Matsuo N, et al. Effect of diabetes on incidence of peritoneal dialysis-associated peritonitis. PLoS ONE. 2019;14(12):e0225316.","journal-title":"PLoS ONE"},{"issue":"4","key":"3431_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/089686080502500413","volume":"25","author":"KM Chow","year":"2005","unstructured":"Chow KM, Szeto CC, Leung CB, Kwan BC, Law MC, Li PK. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Perit Dial Int. 2005;25(4):374\u20139.","journal-title":"Perit Dial Int"},{"issue":"2","key":"3431_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1053\/j.ajkd.2004.10.008","volume":"45","author":"TN Oo","year":"2005","unstructured":"Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis. 2005;45(2):372\u201380.","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"3431_CR29","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJM199912163412507","volume":"341","author":"N Joshi","year":"1999","unstructured":"Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999;341(25):1906\u201312.","journal-title":"N Engl J Med"},{"issue":"5963","key":"3431_CR30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.1184003","volume":"327","author":"K Schroder","year":"2010","unstructured":"Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327(5963):296\u2013300.","journal-title":"Science"},{"issue":"8","key":"3431_CR31","doi-asserted-by":"publisher","first-page":"e72344","DOI":"10.1371\/journal.pone.0072344","volume":"8","author":"L Fang","year":"2013","unstructured":"Fang L, Xie D, Wu X, Cao H, Su W, Yang J. Involvement of endoplasmic reticulum stress in albuminuria induced inflammasome activation in renal proximal tubular cells. PLoS ONE. 2013;8(8):e72344.","journal-title":"PLoS ONE"},{"issue":"6","key":"3431_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/1744-9987.12589","volume":"21","author":"K Uchiyama","year":"2017","unstructured":"Uchiyama K, Yanai A, Maeda K, Ono K, Honda K, Tsujimoto R, et al. Baseline and time-averaged values predicting residual renal function decline rate in Japanese peritoneal dialysis patients. Ther Apher Dial. 2017;21(6):599\u2013605.","journal-title":"Ther Apher Dial"},{"issue":"2\u20133","key":"3431_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000350145","volume":"37","author":"SH Kang","year":"2013","unstructured":"Kang SH, Cho KH, Park JW, Yoon KW, Do JY. Proteinuria as a risk factor for decline in residual renal function in non-diabetic peritoneal dialysis patients. Kidney Blood Press Res. 2013;37(2\u20133):199\u2013210.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"3431_CR34","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1046\/j.1523-1755.2002.00505.x","volume":"62","author":"MA Jansen","year":"2002","unstructured":"Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002;62(3):1046\u201353.","journal-title":"Kidney Int"},{"issue":"12","key":"3431_CR35","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.2215\/CJN.00630117","volume":"12","author":"R Whitty","year":"2017","unstructured":"Whitty R, Bargman JM, Kiss A, Dresser L, Lui P. Residual kidney function and peritoneal dialysis-associated peritonitis treatment outcomes. Clin J Am Soc Nephrol. 2017;12(12):2016\u201322.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03431-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03431-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03431-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T01:04:12Z","timestamp":1703034252000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03431-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3431"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03431-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"17 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was designed in accordance with the Helsinki Declaration, and was approved by Kawasaki Medical School Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"374"}}